Biotech · Private company
Cornerstone Pharmaceuticals
Track this companyFree. Adds Cornerstone Pharmaceuticals to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- CPI 613, mFolfirinoxPhase 3 · Pancreatic Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- CPI-613 + High Dose Cytarabine and MitoxantronePhase 3 · Relapsed/Refractory Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Fludarabine, Cytarabine, FilgrastimPhase 3 · Relapsed/Refractory Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- FolfirinoxPhase 3 · Pancreatic Cancer MetastaticClinicalTrials.gov · fetched Nov 12, 2026
- High Dose Cytarabine and MitoxantronePhase 3 · Relapsed/Refractory Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- Mitoxantrone, Etoposide and CytarabinePhase 3 · Relapsed/Refractory Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- CPI-613 + HydroxychloroquinePhase 2 · Sarcoma, Clear CellClinicalTrials.gov · fetched Nov 12, 2026
- CPI-613, modified FolfirinoxPhase 2 · Pancreatic Cancer Stage IVClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic CancerPHASE2 · WITHDRAWN · started Aug 15, 2024ClinicalTrials.gov NCT06518538 · fetched Nov 12, 2026
- CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic AdenocarcinomaPHASE1 · TERMINATED · started Oct 31, 2022ClinicalTrials.gov NCT05325281 · fetched Nov 12, 2026
- To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft TissuePHASE1_PHASE2 · COMPLETED · started Sep 1, 2021ClinicalTrials.gov NCT04593758 · fetched Nov 12, 2026
- Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AMLPHASE3 · TERMINATED · started Nov 12, 2018ClinicalTrials.gov NCT03504410 · fetched Nov 12, 2026
- Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the PancreasPHASE3 · COMPLETED · started Nov 9, 2018ClinicalTrials.gov NCT03504423 · fetched Nov 12, 2026